SCHEMBL1658574

SCHEMBL1658574

Fc1ccc(Nc2nc(Cl)nc(Cl)n2)cc1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TXN P10599 1/20 0.89
NFKB1 P19838 3/20 0.64
APP P05067 3/20 0.60
MAPT P10636 4/20 0.59
MEN1 O00255 2/20 0.59
MAPK1 P28482 2/20 0.59
KMT2A Q03164 2/20 0.59
CA12 O43570 2/20 0.56
CA1 P00915 2/20 0.56
CA2 P00918 2/20 0.56
CA9 Q16790 2/20 0.56
CA14 Q9ULX7 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
KDM4E B2RXH2 1/20 0.54
KCNH3 Q9ULD8 3/20 0.53
CHRNA7 P36544 1/20 0.52
POLB P06746 1/20 0.51
LMNA P02545 2/20 0.50
NPC1 O15118 2/20 0.50
ALOX12 P18054 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21645541 1.00 TXN (0.89) TXNNFKB1APPMAPTMEN1
SCHEMBL535866 0.96 TXN (0.82) TXNNFKB1APPMAPTMEN1
SCHEMBL20511159 0.94 TXN (1.00) TXNNFKB1APPMAPTMEN1
SCHEMBL11837292 0.89 NFKB1 (0.78) TXNNFKB1APPMAPTMEN1
SCHEMBL1925527 0.89 MEN1 (0.79) TXNNFKB1APPMAPTMEN1
SCHEMBL28736406 0.87 TXN (0.70) TXNNFKB1APPMAPTMEN1
SCHEMBL1924287 0.87 APP (0.70) TXNNFKB1APPMAPTMEN1
SCHEMBL21645364 0.83 GAA (0.68) TXNNFKB1APPMAPTMEN1
SCHEMBL13950835 0.83 TXN (0.64) TXNNFKB1APPMAPTCA1
SCHEMBL3500246 0.83 NFKB1 (0.69) TXNNFKB1APPMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368184-A1 PIKfyve Inhibitors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2024-11-07 US disclosed
US-12030896-B2 PIKfyve inhibitors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2024-07-09 US disclosed
US-12030896-B2 PIKfyve inhibitors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2024-07-09 US disclosed
US-12030896-B2 PIKfyve inhibitors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2024-07-09 US disclosed
CN-108191774-B Heterocyclic compound, preparation method and application thereof 中国药科大学 2022-05-24 CN disclosed
US-20210139505-A1 PIKfyve Inhibitors Sanford Burnham Prebys Medical Discovery Institute 2021-05-13 US disclosed
US-20210139505-A1 PIKfyve Inhibitors Sanford Burnham Prebys Medical Discovery Institute 2021-05-13 US disclosed
EP-3817736-A1 PIKFYVE INHIBITORS Mayo Foundation for Medical Education and Research (US) 2021-05-12 EP disclosed
WO-2019241787-A9 NOVEL CYCLIC GMP-AMP SYNTHASE (CGAS) INHIBITORS AND THEIR METHOD OF USE THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (US) 2020-02-06 WO disclosed
EP-2152676-B1 \"TRIAZINE DERIVATIVES, COMPOSITIONS CONTAINING SUCH DERIVATIVES, AND METHODS OF TREATMENT OF CANCER AND AUTOIMMUNE DISEASES USING SUCH DERIVATIVES\ PROMETIC BIOSCIENCES INC (CA) 2013-04-03 EP disclosed
US-20100129350-A1 Triazine Derivatives, Compositions Containing Such Derivatives, and Methods of Treatment of Cancer and Autoimmune Diseases Using Such Derivatives PROMETIC BIOSCIENCES INC. (CA) 2010-05-27 US disclosed
EP-2152676-A1 \"TRIAZINE DERIVATIVES, COMPOSITIONS CONTAINING SUCH DERIVATIVES, AND METHODS OF TREATMENT OF CANCER AND AUTOIMMUNE DISEASES USING SUCH DERIVATIVES\ ProMetic BioSciences Inc. (CA) 2010-02-17 EP disclosed
WO-2008131547-A1 'TRIAZINE DERIVATIVES, COMPOSITIONS CONTAINING SUCH DERIVATIVES, AND METHODS OF TREATMENT OF CANCER AND AUTOIMMUNE DISEASES USING SUCH DERIVATIVES' PROMETIC BIOSCIENCES INC. (CA) 2008-11-06 WO disclosed
WO-2008131547-A1 'TRIAZINE DERIVATIVES, COMPOSITIONS CONTAINING SUCH DERIVATIVES, AND METHODS OF TREATMENT OF CANCER AND AUTOIMMUNE DISEASES USING SUCH DERIVATIVES' PROMETIC BIOSCIENCES INC. (CA) 2008-11-06 WO disclosed
US-20080255126-A1 Inhibitors of post-proline cleaving proteases FERRING B.V. 2008-10-16 US disclosed
US-7335677-B2 Inhibitors of dipeptidyl peptidase IV FERRING B.V. (NL) 2008-02-26 US disclosed
US-20050043299-A1 Inhibitors of dipeptidyl peptidase iv FERRING B. V. 2005-02-24 US disclosed
EP-1446116-A1 INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FERRING B.V. (NL) 2004-08-18 EP disclosed
WO-2003035057-A1 INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FERRING B.V. (NL) 2003-05-01 WO disclosed
US-3931165-A INSECTICIDES, HERBICIDES BARER SOL J 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030896-B2 PIKfyve inhibitors PIKFYVE, PIP4K2B, PIP4K2A TXN 4109/4885NFKB1 2785/4885APP 4389/4885
US-20210139505-A1 PIKfyve Inhibitors PIKFYVE, PIP4K2B, PIP4K2A TXN 4109/4885NFKB1 2785/4885APP 4389/4885
US-20240368184-A1 PIKfyve Inhibitors PIKFYVE, PIP4K2B, PIP4K2A TXN 4109/4885NFKB1 2785/4885APP 4389/4885
US-20100129350-A1 Triazine Derivatives, Compositions Containing Such Derivatives, and Methods of Treatment of Cancer and Autoimmune Diseases Using Such Derivatives FLT3, SETD2, SETD7 TXN 298/4885NFKB1 1502/4885APP 4726/4885
US-20050043299-A1 Inhibitors of dipeptidyl peptidase iv DPP4, DPP9, DPP3 TXN 1996/4885NFKB1 3877/4885APP 1105/4885
US-20080255126-A1 Inhibitors of post-proline cleaving proteases PREP, PEPD, DPP4 TXN 1923/4885NFKB1 2961/4885APP 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.